CCN2 and diabetic kidney disease: In a recent phase I clinical study, a human monoclonal antibody to CCN2, FG-3019, was intravenously administered to patients with microalbuminuric diabetic kidney disease (DKD) (n = 24) with the dose of 3 or 10 mg/kg every 2 weeks for four doses and then followed up at days 62 and 365.